Non-invasive test for the screening of endometrial cancer and precancerous lesions
MyEndom
MyEndom is the first highly accurate non-invasive test for the screening of endometrial cancer and precancerous lesions.
MyEndom enables the detection of early molecular and cellular alterations associated with endometrial cancer. By identifying abnormalities that may indicate the presence of precancerous or malignant changes, the test serves as an effective first-line screening tool.
When these findings are confirmed through diagnostic methods, endometrial cancer can be detected at an earlier stage, when treatment is less invasive and clinical outcomes are significantly improved.
Who is the Test Recommended For
- Women of childbearing age with abnormal vaginal bleeding, abnormal endometrial thickening (≥12 mm)
- Peri / postmenopausal women with abnormal vaginal bleeding, abnormal endometrial thickening (≥5 mm)
- Duration of menstrual flow greater than 7 days
- Taking Tamoxifen (active ingredient in non-steroidal anti-estrogen drugs)
- Women with Lynch Syndrome (hereditary non-polyposis colorectal cancer)
- Personal history of breast or ovarian cancer
- Family history of endometrial cancer (mothers – daughters – sisters)
- Obese or heavily overweight women
Why Screening Matters
The Importance Of Early Diagnosis
Early diagnosis is of vital importance because it makes therapy less invasive and, at the same time, more effective.
Statistical Information On Endometrial Cancer
- It is the fifth most diagnosed cancer in women
- It is the most common among gynecological cancers
- It is more common in the 50-70 age group
Risk Factors
Risk factors are quite general and cross-cutting in the general population, both men and women.
Metabolic Risk Factors
Overweight women are at increased risk for endometrial cancer. Some studies have shown that in obese women the risk is even 5 times higher than in normal weight peers. The so-called metabolic syndrome (diabetes, obesity, hypertension) also increases the risk of developing endometrial cancer.
Hormonal Risk Factors
Unbalanced estrogen activity from progesterone increases the risk of developing endometrial cancer.
The risk, therefore, increases in all cases in which exposure to estrogen increases:
- Early menarche
- Late menopause
- Absence of pregnancies
- Taking tamoxifen
- Ovarian polycystosis
- Estrogen-only hormone replacement therapy (HRT)
Genetic Risk Factors
Women with Lynch syndrome have a high risk (one in two) of developing endometrial cancer later in life. This hereditary syndrome causes about 5% of all endometrial cancers.
A history of breast or ovarian cancer or a family history of endometrial cancer (mother, sister or daughter) increases the risk of developing one.
Advantages of the MyEndom Test
- It is the first highly accurate non-invasive test for endometrial cancer screening
- It is able to effectively distinguish uterine fibroids from endometrial cancer
- The ability of the test to correctly identify an anomaly is 88%
- The ability of the test to correctly identify a healthy subject is 93%
How the Test is Performed
The patient’s DNA is used to perform the MyEndom test.
The DNA is extracted from a sample of exfoliated cells taken at the height of the uterine endo-exocervical junction and subjected to a specific analysis to detect any methylation abnormalities in endometrial cancer marker genes (CDO1-CELF4).
Request Information About MyEndom
Contact us today to learn more about the MyEndom screening test and schedule your appointment.
Contact Us Now
